The studies aim to improve early detection of chronic lung allograft dysfunction (CLAD), the leading cause of lung transplant failures.
Site Search
The Cystic Fibrosis Foundation's successful business model was at the center of a congressional briefing in Washington, D.C., today, which focused on strategies for jump-starting drug development for rare diseases.
Corbus Pharmaceuticals reported promising results Thursday from an early stage clinical study of a potential anti-inflammatory drug for people with cystic fibrosis.
CF Foundation President and CEO Robert J. Beall, Ph.D. testified today before the House of Representatives' Energy and Commerce Committee at a hearing entitled, “21st Century Cures: Incorporating the Patient Perspective.”
Today, the Cystic Fibrosis Foundation announced plans to improve lung transplantation for people with CF at an Organ Summit, hosted by the White House. The event focused on new and innovative ways to improve outcomes for individuals waiting for organ transplants and to improve support for living donors.
Piper Beatty, a two-time double-lung transplant recipient, testifies at an FDA meeting on organ transplantation.
The studies aim to improve our understanding of a common cause of lung transplant failures, a condition known as chronic lung allograft dysfunction (CLAD).
The Cystic Fibrosis Foundation awarded Talee Bio Inc. up to $4.5 million to develop methods for delivering potential gene therapy treatments to the lungs.
The U.S. Food and Drug Administration has approved the use of the triple-combination modulator elexacaftor/tezacaftor/ivacaftor (Trikafta™) for people with cystic fibrosis ages 12 and older who have at least one copy of the F508del mutation.